SG11202111985XA - Engineered chimeric fusion protein compositions and methods of use thereof - Google Patents
Engineered chimeric fusion protein compositions and methods of use thereofInfo
- Publication number
- SG11202111985XA SG11202111985XA SG11202111985XA SG11202111985XA SG11202111985XA SG 11202111985X A SG11202111985X A SG 11202111985XA SG 11202111985X A SG11202111985X A SG 11202111985XA SG 11202111985X A SG11202111985X A SG 11202111985XA SG 11202111985X A SG11202111985X A SG 11202111985XA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- fusion protein
- protein compositions
- chimeric fusion
- engineered chimeric
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464458—Proteinases
- A61K39/464461—Caspases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962841190P | 2019-04-30 | 2019-04-30 | |
US201962841183P | 2019-04-30 | 2019-04-30 | |
US16/827,302 US11013764B2 (en) | 2019-04-30 | 2020-03-23 | Engineered phagocytic receptor compositions and methods of use thereof |
US16/827,381 US11026973B2 (en) | 2019-04-30 | 2020-03-23 | Engineered phagocytic receptor compositions and methods of use thereof |
PCT/US2020/030837 WO2020223550A1 (en) | 2019-04-30 | 2020-04-30 | Engineered chimeric fusion protein compositions and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202111985XA true SG11202111985XA (en) | 2021-11-29 |
Family
ID=73029265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202111985XA SG11202111985XA (en) | 2019-04-30 | 2020-04-30 | Engineered chimeric fusion protein compositions and methods of use thereof |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP3962497A4 (en) |
JP (1) | JP2022531325A (en) |
KR (1) | KR20220045930A (en) |
CN (1) | CN114072157A (en) |
AU (1) | AU2020266595A1 (en) |
BR (1) | BR112021021843A8 (en) |
CA (1) | CA3135531A1 (en) |
GB (1) | GB2600834A (en) |
IL (1) | IL287650A (en) |
MX (1) | MX2021013355A (en) |
SG (1) | SG11202111985XA (en) |
WO (1) | WO2020223550A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
CA3073421A1 (en) | 2017-09-26 | 2019-04-04 | Daniel Mark COREY | Chimeric engulfment receptor molecules and methods of use |
MX2020007024A (en) | 2018-01-03 | 2020-10-28 | Palleon Pharmaceuticals Inc | Recombinant human sialidases, sialidase fusion proteins, and methods of using the same. |
AU2020341479A1 (en) | 2019-09-03 | 2022-03-31 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
JP2023549140A (en) | 2020-11-04 | 2023-11-22 | マイエロイド・セラピューティクス,インコーポレーテッド | Engineered chimeric fusion protein compositions and methods of use thereof |
CA3173668A1 (en) * | 2021-01-06 | 2022-07-14 | Li Peng | Sialidase-her2-antibody fusion proteins and methods of use thereof |
CN117480178A (en) | 2021-04-28 | 2024-01-30 | 桑昆专利有限公司 | Chimeric FC-alpha receptors and uses thereof |
CN113214408B (en) * | 2021-04-30 | 2022-12-27 | 清华大学深圳国际研究生院 | Chimeric antigen receptor macrophage and preparation method and application thereof |
GB202108366D0 (en) * | 2021-06-11 | 2021-07-28 | Quell Therapeutics Ltd | Multichain chimeric antigen receptor |
CN113817677B (en) * | 2021-09-29 | 2023-08-18 | 四川大学 | Use of pantothenic acid or derivatives thereof and alpha-D-glucose-1, 6-biphosphoric acid or derivatives thereof for promoting DC migration |
WO2023194608A1 (en) * | 2022-04-07 | 2023-10-12 | Institut Curie | Myeloid cells modified by chimeric antigen receptor and uses thereof for anti-cancer therapy |
WO2023194607A1 (en) * | 2022-04-07 | 2023-10-12 | Institut Curie | Myeloid cells modified by chimeric antigen receptor with cd40 and uses thereof for anti-cancer therapy |
KR20230162310A (en) * | 2022-05-20 | 2023-11-28 | 주식회사 카나프테라퓨틱스 | Fusion protein comprising light protein and anti-fap antibody and use thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016138034A1 (en) * | 2015-02-24 | 2016-09-01 | The Regents Of The University Of California | Binding-triggered transcriptional switches and methods of use thereof |
WO2016172606A1 (en) * | 2015-04-23 | 2016-10-27 | Baylor College Of Medicine | Cd5 chimeric antigen receptor for adoptive t cell therapy |
IL297905A (en) * | 2015-07-28 | 2023-01-01 | Univ Pennsylvania | Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof |
CN108137704A (en) * | 2015-10-13 | 2018-06-08 | 迅雷生物科技有限公司 | Macrophage CAR in immunotherapy(MOTO-CAR) |
WO2019055946A1 (en) * | 2017-09-18 | 2019-03-21 | F1 Oncology, Inc. | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof |
US20180186855A1 (en) * | 2016-03-23 | 2018-07-05 | Alector Llc | Chimeric receptors and methods of use thereof |
CA3018382A1 (en) * | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
US20200055917A1 (en) * | 2016-09-27 | 2020-02-20 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
WO2018073394A1 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Cell death inducing chimeric antigen receptors |
KR20190070977A (en) * | 2016-11-01 | 2019-06-21 | 젠맵 비. 브이 | Polypeptide variants and uses thereof |
WO2018140831A2 (en) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
-
2020
- 2020-04-30 JP JP2021564784A patent/JP2022531325A/en active Pending
- 2020-04-30 CN CN202080048311.9A patent/CN114072157A/en active Pending
- 2020-04-30 SG SG11202111985XA patent/SG11202111985XA/en unknown
- 2020-04-30 WO PCT/US2020/030837 patent/WO2020223550A1/en unknown
- 2020-04-30 MX MX2021013355A patent/MX2021013355A/en unknown
- 2020-04-30 AU AU2020266595A patent/AU2020266595A1/en active Pending
- 2020-04-30 BR BR112021021843A patent/BR112021021843A8/en unknown
- 2020-04-30 KR KR1020217038628A patent/KR20220045930A/en unknown
- 2020-04-30 CA CA3135531A patent/CA3135531A1/en active Pending
- 2020-04-30 GB GB2115849.8A patent/GB2600834A/en active Pending
- 2020-04-30 EP EP20798060.8A patent/EP3962497A4/en active Pending
-
2021
- 2021-10-28 IL IL287650A patent/IL287650A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021021843A8 (en) | 2022-06-21 |
MX2021013355A (en) | 2022-02-21 |
AU2020266595A1 (en) | 2021-11-25 |
CA3135531A1 (en) | 2020-11-05 |
EP3962497A1 (en) | 2022-03-09 |
EP3962497A4 (en) | 2023-01-18 |
CN114072157A (en) | 2022-02-18 |
KR20220045930A (en) | 2022-04-13 |
JP2022531325A (en) | 2022-07-06 |
BR112021021843A2 (en) | 2022-02-15 |
GB2600834A (en) | 2022-05-11 |
IL287650A (en) | 2021-12-01 |
WO2020223550A1 (en) | 2020-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL287650A (en) | Engineered chimeric fusion protein compositions and methods of use thereof | |
IL288373A (en) | Flt3l-fc fusion proteins and methods of use | |
IL279965A (en) | Fusion constructs and methods of using thereof | |
SG11202012004SA (en) | Rna-targeting fusion protein compositions and methods for use | |
IL280102A (en) | Pd1-4-1bbl variant fusion protein and methods of use thereof | |
EP3585425A4 (en) | Methods of making and using extracellular domain-based chimeric proteins | |
IL287407A (en) | Chimeric receptors and methods of use thereof | |
EP3152238A4 (en) | Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof | |
IL279505A (en) | Chimeric transmembrane proteins and uses thereof | |
GB202307301D0 (en) | Engineered chimeric fusion protein compositions and methods of use thereof | |
ZA202102034B (en) | Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies | |
IL280103A (en) | Sirpalpha-4-1bbl variant fusion protein and methods of use thereof | |
SG11202103151RA (en) | Frataxin expression constructs having engineered promoters and methods of use thereof | |
EP3515493A4 (en) | Chimeric antigen receptors and compositions and methods of use thereof | |
SG11202106585UA (en) | Polishing compositions and methods of using same | |
IL280280A (en) | Compositions of fcrn antibodies and methods of use thereof | |
SG11202110400QA (en) | Fusion protein and use thereof | |
SG11202106584QA (en) | Polishing compositions and methods of using same | |
EP3980067A4 (en) | Antibody-interleukin fusion protein and methods of use | |
SG11202104912SA (en) | Fusion protein and use thereof | |
EP3600429A4 (en) | Il-37 fusion protein and methods of making and using same | |
EP3927830A4 (en) | Chimeric polypeptides and methods of using the same | |
IL286799A (en) | Fusion constructs and uses thereof | |
GB202314244D0 (en) | Engineered chimeric fusion protein compositions and methods of use thereof | |
EP3998282A4 (en) | Novel fusion protein and use of same |